Yahoo
KOSDAQ - Delayed Quote KRW

Medy-Tox Inc. (086900.KQ)

63,500.00 -400.00 (-0.63%)
As of 11:05:28 AM GMT+9. Market Open.
Chart Range Bar
Loading chart for 086900.KQ
  • Previous Close 63,900.00
  • Open 63,000.00
  • Bid 63,400.00 x --
  • Ask 63,600.00 x --
  • Day's Range 63,000.00 - 65,100.00
  • 52 Week Range 61,600.00 - 141,100.00
  • Volume 1,148
  • Avg. Volume 22,819
  • Market Cap (intraday) 410.099B
  • Beta (5Y Monthly) 0.39
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date (est.) --
  • Forward Dividend & Yield 2,400.00 (3.76%)
  • Ex-Dividend Date Oct 28, 2026
  • 1y Target Est 86,250.00

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials. In addition, it provides various medical devices, such as ComfortDual for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; and Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method. It also exports its products to approximately 60 countries, including Japan, Brazil, and internationally. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea.

www.medytox.com

703

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

086900.KQ
46.23%
KOSPI Composite Index (^KS11)
34.60%

1-Year Return

086900.KQ
45.96%
KOSPI Composite Index (^KS11)
38.09%

3-Year Return

086900.KQ
69.94%
KOSPI Composite Index (^KS11)
142.07%

5-Year Return

086900.KQ
53.11%
KOSPI Composite Index (^KS11)
88.22%

Earnings Trends

View More

Earnings Per Share (Normalized)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 68.7B
Earnings 3.11B
Profit Margin 4.52%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
20B
40B
60B
0.0%
5.0%
10.0%

Analyst Insights

View More

Analyst Price Targets

60,000.00
86,250.00 Average
63,500.00 Current
120,000.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.10%

  • Return on Assets (ttm)

    1.84%

  • Return on Equity (ttm)

    3.59%

  • Revenue (ttm)

    251.08B

  • Net Income Avi to Common (ttm)

    14.34B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    47.98B

  • Total Debt/Equity (mrq)

    32.85%

  • Levered Free Cash Flow (ttm)

    37.63B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: